Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
5(33%)
Results Posted
71%(5 trials)
Terminated
1(7%)

Phase Distribution

Ph phase_1
4
27%
Ph phase_3
2
13%
Ph phase_2
8
53%
Ph phase_4
1
7%

Phase Distribution

4

Early Stage

8

Mid Stage

3

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
4(26.7%)
Phase 2Efficacy & side effects
8(53.3%)
Phase 3Large-scale testing
2(13.3%)
Phase 4Post-market surveillance
1(6.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

70.0%

7 of 10 finished

Non-Completion Rate

30.0%

3 ended early

Currently Active

5

trials recruiting

Total Trials

15

all time

Status Distribution
Active(5)
Completed(7)
Terminated(3)

Detailed Status

Completed7
Recruiting3
Withdrawn2
Active, not recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
5
Success Rate
87.5%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (26.7%)
Phase 28 (53.3%)
Phase 32 (13.3%)
Phase 41 (6.7%)

Trials by Status

recruiting320%
terminated17%
withdrawn213%
active_not_recruiting213%
completed747%

Recent Activity

5 active trials
Showing 5 of 15
completedphase_1

Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants

NCT06753955
recruitingphase_3

Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis

NCT07299695
withdrawnphase_2

Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome

NCT05701189
active_not_recruitingphase_2

Therapies for Down Syndrome Regression Disorder

NCT05662228
active_not_recruitingphase_2

BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)

NCT05156710
View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT06753955Phase 1

Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants

Completed
NCT07299695Phase 3

Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis

Recruiting
NCT05701189Phase 2

Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome

Withdrawn
NCT05662228Phase 2

Therapies for Down Syndrome Regression Disorder

Active Not Recruiting
NCT05156710Phase 2

BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)

Active Not Recruiting
NCT06954441Phase 3

V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency

Recruiting
NCT05494593Phase 4

A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)

Withdrawn
NCT07202052Phase 2

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)

Recruiting
NCT03866577Phase 1

Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients

Terminated
NCT02690038Phase 2

Ig PRx in AECOPD: Pilot Study

Completed
NCT01854827Phase 1

Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia

Completed
NCT00176865Phase 2

Stem Cell Transplant for Immunologic or Histiocytic Disorders

Completed
NCT00750867Phase 2

Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins

Completed
NCT00271570Phase 1

Infliximab (Remicade) for Patients With Acute Kawasaki Disease

Completed
NCT00001287Phase 2

Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Completed

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15